CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,461,736 | +133.7% | 116,400 | +41.6% | 0.00% | +200.0% |
| Q2 2023 | $1,481,244 | +13.4% | 82,200 | +1.1% | 0.00% | 0.0% |
| Q1 2023 | $1,305,678 | -21.4% | 81,300 | -10.5% | 0.00% | 0.0% |
| Q4 2022 | $1,661,640 | -3.8% | 90,800 | +3.2% | 0.00% | 0.0% |
| Q3 2022 | $1,728,000 | +5.3% | 88,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,641,000 | -5.0% | 88,000 | +11.8% | 0.00% | 0.0% |
| Q1 2022 | $1,727,000 | -14.4% | 78,700 | +10.8% | 0.00% | 0.0% |
| Q4 2021 | $2,017,000 | +93.2% | 71,000 | +43.1% | 0.00% | 0.0% |
| Q3 2021 | $1,044,000 | +11.7% | 49,600 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $935,000 | +62.6% | 49,600 | +31.9% | 0.00% | – |
| Q1 2021 | $575,000 | +12.5% | 37,600 | +3.9% | 0.00% | – |
| Q4 2020 | $511,000 | -9.9% | 36,200 | 0.0% | 0.00% | – |
| Q3 2020 | $567,000 | -10.6% | 36,200 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $634,000 | +129.7% | 36,200 | +92.6% | 0.00% | – |
| Q1 2020 | $276,000 | -38.5% | 18,800 | +5.0% | 0.00% | – |
| Q4 2019 | $449,000 | +66.9% | 17,900 | 0.0% | 0.00% | – |
| Q3 2019 | $269,000 | -40.0% | 17,900 | 0.0% | 0.00% | – |
| Q2 2019 | $448,000 | – | 17,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $76,819,000 | 7.66% |
| RA Capital Management | 1,875,209 | $42,680,000 | 1.84% |
| Perceptive Advisors | 2,587,953 | $58,901,000 | 1.66% |
| EMORY UNIVERSITY | 97,035 | $2,209,000 | 1.55% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $3,817,000 | 1.05% |
| Orbimed Advisors | 1,914,282 | $43,569,000 | 0.67% |
| Opaleye Management Inc. | 73,000 | $1,661,000 | 0.46% |
| Novo Holdings A/S | 135,009 | $3,073,000 | 0.46% |
| Virtus ETF Advisers LLC | 7,934 | $181,000 | 0.38% |
| Eventide Asset Management | 384,000 | $8,740,000 | 0.30% |